Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera

Abstract

<p>Abstract</p> <p>Background</p> <p>American Trypanosomiasis or Chagas disease is caused by <it>Trypanosoma cruzi </it>which currently infects approximately 16 million people in the Americas causing high morbidity and mortality. Diagnosis of American trypanosomiasis relies on serology, primarily using indirect immunofluorescence assay (IFA) with <it>T. cruzi </it>epimastigote forms. The closely related but nonpathogenic <it>Trypanosoma rangeli </it>has a sympatric distribution with <it>T. cruzi </it>and is carried by the same vectors. As a result false positives are frequently generated. This confounding factor leads to increased diagnostic test costs and where false positives are not caught, endangers human health due to the toxicity of the drugs used to treat Chagas disease.</p> <p>Results</p> <p>In the present study, serologic cross-reactivity between the two species was compared for the currently used epimastigote form and the more pathologically relevant trypomastigote form, using IFA and immunoblotting (IB) assays. Our results reveal an important decrease in cross reactivity when <it>T. rangeli </it>culture-derived trypomastigotes are used in IFA based diagnosis of Chagas disease. Western blot results using sera from both acute and chronic chagasic patients presenting with cardiac, indeterminate or digestive disease revealed similar, but not identical, antigenic profiles.</p> <p>Conclusion</p> <p>This is the first study addressing the serological cross-reactivity between distinct forms and strains of <it>T. rangeli </it>and <it>T. cruzi </it>using sera from distinct phases of the Chagasic infection. Several <it>T. rangeli</it>-specific proteins were detected, which may have potential as diagnostic tools.</p